Pulse operated flow path selector valve assembly Final test report

Operational test and evaluation of pulse operated flow path selector valve assembl

Sequential Adaptive Detection for In-Situ Transmission Electron Microscopy (TEM)

We develop new efficient online algorithms for detecting transient sparse signals in TEM video sequences, by adopting the recently developed framework for sequential detection jointly with online convex optimization [1]. We cast the problem as detecting an unknown sparse mean shift of Gaussian observations, and develop adaptive CUSUM and adaptive SSRS procedures, which are based on likelihood ratio statistics with post-change mean vector being online maximum likelihood estimators with $\ell_1$. We demonstrate the meritorious performance of our algorithms for TEM imaging using real data

Effets de paramètres d'opération sur la décantation de boues biologiques d'une unité de traitement d'eaux usées de raffinerie

La qualité de l'effluent des systèmes de biotraitement par boues activées est souvent limitée par la performance de l'unité de décantation. Cette étude analyse les causes possibles des difficultés d'opération rencontrées dans la décantation des boues évacuées aux décanteurs secondaires d'une raffinerie de pétrole. Les objectifs visent à déterminer et à quantifier l'effet des paramètres d'opération qui affectent le fonctionnement du décanteur, en les reliant si possible à son mauvais fonctionnement, à évaluer de l'ajout d'alun et à proposer des méthodes correctives pour améliorer l'efficacité de décantation.L'étude montre que :- l'efficacité des décanteurs sera améliorée si le niveau d'oxygène dissous et la concentration en matières totales en suspension (MTS) dans le bassin d'aération sont respectivement maintenus entre 0,9 à 1,3 ppm et 4 300 à 4 800 mg/L;- le pH de la liqueur mixte ne semble pas influencer la décantabitité;- l'addition d'alun doit être évitée ou maintenue inférieure à 50 mg/L;- l'agitation et les vitesses linéaires élevées dans les conduites d'alimentation des décanteurs doivent être évitées.The wastewater treatment systems built in the seventies for treating the effluents from oil refineries often fail to comply with new environmental standards. The present study focuses mainly on the problem of sludge settling in the clarifiers. The purpose of this work was to determine the effect of various parameters on the settling characteristics of the activated sludge, to evaluate the rote of alun as a flocculating agent and to characterize the operation of the clarifiers primarily as it relates to the settling problem. The influence of the quantity of the alun added and of the stirring speed on the settling characteristics of the sludge were determined in jar tests. The effects, on the performance of the clarifiers, of the level of dissolved oxygen in the bioreactor, of the pH and of the concentration in total suspended solids (TSS) maintained in the mixed liquor, were also investigated.The studies on the sludge settleability led to the following conclusions :- the concentration in dissolved oxygen and the concentration in TSS in the aeration tank are two parameters which have a critical effect on the effluent quality. The optimal operating intervals for these parameters are from 0.9 to 1.3 ppm for dissolved oxygen and from 4 300 to 4 800 mg/L for the TSS;- the pH of the mixed liquor is not a main factor and does not seem to have any effect on the sludge settleability;- the addition of alum in excess of 50 mg/L has an adverse effect on the sludge settling characteristics. Addition of alum below this level, however, improves the clarity of the residual liquor. Nevertheless, the addition of this flocculating agent is not recommended;- the high flowrates and violent mixing in the piping system used to feed the mixed liquor from the aeration tank to the clarifiers adversely affects the solid-liquid separation in the clarifiers.By simply stopping the addition of the flocculating agent, maintaining the dissolved oxygen concentration between 1 to 2 ppm and the TSS between 4 300 to 4 800 mg/L in the wastewater treatment unit, it was possible to improve substantially the quality of the effluent and thus meet the environmental standards

Autonomic Nervous System and Neurocardiac Physiopathology

The autonomic nervous system regulates multiple physiological functions; how distinct neurons in peripheral autonomic and intrathoracic ganglia communicate remains to be established. Increasing focus is being paid to functionality of the neurocardiac axis and crosstalk between the intrinsic nervous system and diverse organ systems. Current findings indicate that progression of cardiovascular disease comprises peripheral and central aspects of the cardiac nervous system hierarchy. Indeed, autonomic neuronal dysfunction is known to participate in arrhythmogenesis and sudden cardiac death; diverse interventions (pharmacological, non-pharmacological) that affect neuronal remodeling in the heart following injury caused by cardiovascular disease (congestive heart failure, etc.) or acute myocardial infarction are being investigated. Herein we examine recent findings from clinical and animal studies on the role of the intrinsic cardiac nervous system on regulation of myocardial perfusion and the consequences of cardiac injury. We also discuss different interventions that target the autonomic nervous system, stimulate neuronal remodeling and adaptation, and thereby optimize patient outcomes

Developing conceptual hydrogeological model for Potsdam sandstones in southwestern Quebec, Canada

A hydrogeological study was conducted in Potsdam sandstones on the international border between Canada (Quebec) and the USA (New York). Two sandstone formations, arkose and conglomerate (base) and well-cemented quartz arenite (upper), underlie the study area and form the major regional aquifer unit. Glacial till, littoral sand and gravel, and marine silt and clay discontinuously overlie the aquifer. In both sandstone formations, sub-horizontal bedding planes are ubiquitous and display significant hydraulic conductivities that are orders of magnitude more permeable than the intact rock matrix. Aquifer tests demonstrate that the two formations have similar bulk hydrologic properties, with average hydraulic conductivities ranging from 2×10−5 to 4×10−5 m/s. However, due to their different lithologic and structural characteristics, these two sandstones impose rather different controls on groundwater flow patterns in the study area. Flow is sustained through two types of fracture networks: sub-horizontal, laterally extensive fractures in the basal sandstone, where hydraulic connectivity is very good horizontally but very poor vertically and each of the water-bearing bedding planes can be considered as a separate planar two-dimensional aquifer unit; and the more fractured and vertically jointed system found in the upper sandstone that promotes a more dispersed, three-dimensional movement of groundwater. Une étude hydrogéologique a été entreprise dans les grès de Potsdam, sur la frontière entre le Canada (Québec) et les Etats-Unis (New York). Sous le secteur d’étude, deux formations gréseuses, les arkoses et conglomérats (base) et les arénites quartzeuses cimentées (sommet), forment une unité aquifère majeure à l’échelle régionale. Les moraines glaciaires, les sables et graviers littoraux, et les argiles et silts marins recouvrent l’aquifère de manière discontinue. Dans les deux formations gréseuses, les litages sub-horizontaux sont omniprésents, et présentent des conductivités hydrauliques significatives, supérieures de plusieurs ordres de grandeur à celles de la matrice rocheuse intacte. Les pompages d’essai démontrent que les deux formations ont des propriétés hydrologiques apparentes comparables, avec notamment des conductivités hydrauliques comprises entre 2×10−5 et 4× 10−5 m/s. Cependant, du fait de leurs lithologies et de leurs caractéristiques structurales contrastées, ces deux formations gréseuses imposent des contrôles différents sur les écoulements souterrains dans le secteur d’étude. L’écoulement est soutenu par deux types de réseaux de fractures : des fractures latéralement extensives subhorizontales dans les grès de base, où la connectivité hydraulique est très bonne horizontalement mais médiocre verticalement, et où chacun des plans aquifères peut être considéré comme une unité aquifère isolée plane bidimensionnelle, et un système fissuré verticalement et plus fracturé situé dans les grès supérieurs, qui favorise des écoulements souterrains tridimensionnels et plus dispers

Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial

Objectives: This study assessed whether the benefit of sacubtril/valsartan therapy varied with clinical stability. Background: Despite the benefit of sacubitril/valsartan therapy shown in the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, it has been suggested that switching from an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker should be delayed until occurrence of clinical decompensation. Methods: Outcomes were compared among patients who had prior hospitalization within 3 months of screening (n = 1,611 [19%]), between 3 and 6 months (n = 1,009 [12%]), between 6 and 12 months (n = 886 [11%]), >12 months (n = 1,746 [21%]), or who had never been hospitalized (n = 3,125 [37%]). Results: Twenty percent of patients without prior HF hospitalization experienced a primary endpoint of cardiovascular death or heart failure (HF) hospitalization during the course of the trial. Despite the increased risk associated with more recent hospitalization, the efficacy of sacubitril/valsartan therapy did not differ from that of enalapril according to the occurrence of or time from hospitalization for HF before screening, with respect to the primary endpoint or with respect to cardiovascular or all-cause mortality. Conclusions: Patients with recent HF decompensation requiring hospitalization were more likely to experience cardiovascular death or HF hospitalization than those who had never been hospitalized. Patients who were clinically stable, as shown by a remote HF hospitalization (>3 months prior to screening) or by lack of any prior HF hospitalization, were as likely to benefit from sacubitril/valsartan therapy as more recently hospitalized patients. (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255)

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy

Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the angiotensin-converting enzyme inhibitor enalapril in patients with heart failure and reduced ejection fraction. We examined whether this benefit was consistent irrespective of background therapy. Methods and Results—We examined the effect of study treatment in the following subgroups: diuretics (yes/no), digitalis glycoside (yes/no), mineralocorticoid receptor antagonist (yes/no), and defibrillating device (implanted defibrillating device, yes/no). We also examined the effect of study drug according to β-blocker dose (≥50% and <50% of target dose) and according to whether patients had undergone previous coronary revascularization. We analyzed the primary composite end point of cardiovascular death or heart failure hospitalization, as well as cardiovascular death. Most randomized patients (n=8399) were treated with a diuretic (80%) and β-blocker (93%); 47% of those taking a β-blocker were treated with ≥50% of the recommended dose. In addition, 4671 (56%) were treated with a mineralocorticoid receptor antagonist, 2539 (30%) with digoxin, and 1243 (15%) had a defibrillating device; 2640 (31%) had undergone coronary revascularization. Overall, the sacubitril/valsartan versus enalapril hazard ratio for the primary composite end point was 0.80 (95% confidence interval, 0.73–0.87; P<0.001) and for cardiovascular death was 0.80 (0.71–0.89; P<0.001). The effect of sacubitril/valsartan was consistent across all subgroups examined. The hazard ratio for primary end point ranged from 0.74 to 0.85 and for cardiovascular death ranged from 0.75 to 0.89, with no treatment-by-subgroup interaction. Conclusions—The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent regardless of background therapy and irrespective of previous coronary revascularization or β-blocker dose

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)

Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing the hypothesis that the strategy of simultaneously blocking the renin–angiotensin–aldosterone system and augmenting natriuretic peptides with LCZ696 200 mg b.i.d. is superior to enalapril 10 mg b.i.d. in reducing mortality and morbidity in patients with heart failure and reduced ejection fraction.<p></p> Methods<p></p> Key demographic, clinical and laboratory findings, along with baseline treatment, are reported and compared with those of patients in the treatment arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) and more contemporary drug and device trials in heart failure and reduced ejection fraction.<p></p> Results<p></p> The mean age of the 8442 patients in PARADIGM-HF is 64 (SD 11) years and 78% are male, which is similar to SOLVD-T and more recent trials. Despite extensive background therapy with beta-blockers (93% patients) and mineralocorticoid receptor antagonists (60%), patients in PARADIGM-HF have persisting symptoms and signs, reduced health related quality of life, a low LVEF (mean 29 ± SD 6%) and elevated N-terminal-proB type-natriuretic peptide levels (median 1608 inter-quartile range 886–3221 pg/mL).<p></p> Conclusion<p></p> PARADIGM-HF will determine whether LCZ696 is more beneficial than enalapril when added to other disease-modifying therapies and if further augmentation of endogenous natriuretic peptides will reduce morbidity and mortality in heart failure and reduced ejection fractio